- Home
- CJET vs INDP Comparison
CJET vs INDP Comparison
Compare CJET & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CJET
- INDP
- Stock Information
- Founded
- CJET 2009
- INDP 2000
- Country
- CJET China
- INDP United States
- Employees
- CJET N/A
- INDP N/A
- Industry
- CJET Auto Manufacturing
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- CJET Consumer Discretionary
- INDP Health Care
- Exchange
- CJET Nasdaq
- INDP Nasdaq
- Market Cap
- CJET 11.0M
- INDP 10.2M
- IPO Year
- CJET N/A
- INDP N/A
- Fundamental
- Price
- CJET $2.01
- INDP $0.94
- Analyst Decision
- CJET
- INDP Strong Buy
- Analyst Count
- CJET 0
- INDP 2
- Target Price
- CJET N/A
- INDP $8.50
- AVG Volume (30 Days)
- CJET 9.5K
- INDP 24.7K
- Earning Date
- CJET 12-31-2024
- INDP 11-12-2024
- Dividend Yield
- CJET N/A
- INDP N/A
- EPS Growth
- CJET N/A
- INDP N/A
- EPS
- CJET N/A
- INDP N/A
- Revenue
- CJET $10,275,000.00
- INDP N/A
- Revenue This Year
- CJET N/A
- INDP N/A
- Revenue Next Year
- CJET N/A
- INDP N/A
- P/E Ratio
- CJET N/A
- INDP N/A
- Revenue Growth
- CJET 31.31
- INDP N/A
- 52 Week Low
- CJET $1.77
- INDP $0.84
- 52 Week High
- CJET $30.00
- INDP $3.10
- Technical
- Relative Strength Index (RSI)
- CJET 47.19
- INDP 34.68
- Support Level
- CJET $2.02
- INDP $0.94
- Resistance Level
- CJET $2.07
- INDP $1.06
- Average True Range (ATR)
- CJET 0.13
- INDP 0.05
- MACD
- CJET -0.01
- INDP 0.00
- Stochastic Oscillator
- CJET 25.88
- INDP 0.00
About CJET Chijet Motor Company Inc.
Chijet Motor Co Inc is engaged in the research and development, production and sales of new energy vehicles. New energy vehicles refer to plug-in electric vehicles including battery electric vehicles, plug-in hybrid (PHEV) electric vehicles, and fuel cell electric vehicles. Its passenger vehicles include small cars, sedans, and sports utility vehicles, or SUVs, and commercial vehicles include light trucks and vans.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.